Enovis Co. (NYSE:ENOV) Shares Purchased by King Luther Capital Management Corp

King Luther Capital Management Corp grew its position in shares of Enovis Co. (NYSE:ENOV) by 45.2% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 177,862 shares of the company’s stock after buying an additional 55,385 shares during the period. King Luther Capital Management Corp’s holdings in Enovis were worth $8,039,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. American Century Companies Inc. boosted its holdings in shares of Enovis by 78.6% in the 2nd quarter. American Century Companies Inc. now owns 1,511,871 shares of the company’s stock valued at $68,337,000 after buying an additional 665,208 shares during the period. Wells Fargo & Company MN raised its position in shares of Enovis by 907.7% during the 4th quarter. Wells Fargo & Company MN now owns 559,430 shares of the company’s stock worth $31,339,000 after purchasing an additional 503,913 shares during the period. Diamond Hill Capital Management Inc. lifted its holdings in shares of Enovis by 14.5% in the 2nd quarter. Diamond Hill Capital Management Inc. now owns 2,786,034 shares of the company’s stock worth $125,929,000 after purchasing an additional 352,116 shares during the last quarter. UBS Group AG boosted its position in Enovis by 1,060.8% during the 4th quarter. UBS Group AG now owns 333,510 shares of the company’s stock valued at $18,683,000 after purchasing an additional 304,779 shares during the period. Finally, Boston Partners boosted its position in Enovis by 206.5% during the 1st quarter. Boston Partners now owns 295,969 shares of the company’s stock valued at $18,455,000 after purchasing an additional 199,411 shares during the period. Institutional investors and hedge funds own 98.45% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Needham & Company LLC cut their target price on Enovis from $82.00 to $65.00 and set a “buy” rating on the stock in a research note on Thursday, August 8th. Evercore ISI cut their price objective on shares of Enovis from $70.00 to $62.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 2nd. Finally, JPMorgan Chase & Co. decreased their target price on shares of Enovis from $53.00 to $50.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $69.13.

Enovis Stock Performance

Shares of ENOV opened at $43.65 on Friday. Enovis Co. has a 52-week low of $39.98 and a 52-week high of $65.03. The firm has a market capitalization of $2.39 billion, a PE ratio of -29.10 and a beta of 1.92. The firm has a 50-day moving average price of $44.73 and a 200 day moving average price of $50.05. The company has a quick ratio of 1.08, a current ratio of 2.26 and a debt-to-equity ratio of 0.40.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Wednesday, August 7th. The company reported $0.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.03. Enovis had a negative net margin of 4.73% and a positive return on equity of 4.06%. The business had revenue of $525.20 million during the quarter, compared to analysts’ expectations of $525.99 million. During the same period last year, the firm posted $0.61 earnings per share. The business’s revenue was up 22.6% on a year-over-year basis. On average, sell-side analysts anticipate that Enovis Co. will post 2.7 earnings per share for the current fiscal year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.